Trwa ładowanie...
Notowania

SPH sales revenues for february 2021

Sopharma AD notifies that for February 2021 the Company recorded a decrease in sales of 1% compared to the same month of 2020, incl. 34% increase in domestic sales and 12% decrease in export sales.
In the first two months of 2021 the revenues from sales of production increase by 4% compared to the same period of 2020, incl. 27% increase of sales for the domestic market and 4% decrease in export sales.

Załączniki

Inne komunikaty

DataTytułKursZmiana
2024-09-19
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
12,65
0,00
2024-09-18
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,00
-2,69
2024-09-17
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,00
0,00
2024-09-16
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,00
0,00
2024-09-13
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,20
-4,17
2024-09-12
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
-8,33
2024-09-11
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00
2024-09-10
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00
2024-09-10
SPH Notification from Rositsa Doneva in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00
2024-09-09
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00